The Exosome People - turning the messages your cells send into medicine for aging, inflammation, and tissue repair.
PranaX Corporation. Its logo, photographed for the record. The Houston biotech operates a 7,400 sq ft FDA-registered cGMP facility inside the Levit Green life science campus.
PranaX is a regenerative-medicine biotechnology company with a deceptively simple premise: the body already knows how to repair itself, and much of that instruction travels inside tiny packages called exosomes. These extracellular vesicles - just 30 to 150 nanometers wide - shuttle proteins, lipids, and microRNA between cells, coordinating immune response, tissue regeneration, and cellular communication.
Rather than injecting stem cells, PranaX develops the exosomes those cells release. The distinction matters: it changes the manufacturing, the logistics, and the safety conversation. The company's stated aim is to counter the decline in quality of life associated with aging, inflammation, and tissue damage - and to do it with evidence-based, GMP-manufactured products rather than clinic-to-clinic improvisation.
The science is not homegrown. PranaX holds an exclusive license to a patent portfolio from The University of Texas MD Anderson Cancer Center covering exosome manufacturing, engineering, and therapeutic applications. MD Anderson's original work pointed at oncology, including a Phase I trial targeting KRAS-G12D in pancreatic cancer. PranaX took the rights for everything that is not cancer - aging, inflammation, and degeneration - and built a company around them.
PranaX splits its early commercial strategy into two consumer-facing lines and a longer-horizon clinical pipeline.
A physician-directed, GMP-manufactured stem cell exosome supplement for health and wellness, designed to modulate cellular function and promote tissue regeneration. PranaX's first commercial product.
2026A personal exosome banking service. It collects and cryogenically stores an individual's own exosomes - from peripheral blood, umbilical cord blood, and neonatal tissue - for future regenerative use. Essentially biological insurance.
2026A development pipeline of exosome-based therapeutics targeting age-related chronic disease, inflammation, and tissue degeneration, built on the licensed MD Anderson patent portfolio.
In developmentFounded PranaX around the conviction that exosomes can redefine how we approach aging and long-term wellness. He leads the company's scientific and operational direction and drove the MD Anderson licensing strategy.
Appointed CEO in March 2025. He brings 30+ years in biopharmaceutical manufacturing - most recently as Site Head and exosome Business Leader at Lonza's Lexington, MA facility, where he helped build a 500L-scale GMP exosome process. Earlier roles included VP of Manufacturing Operations at Codiak BioSciences.
The longevity and regenerative-wellness market is crowded with supplement brands and clinics selling stem cell treatments of uncertain provenance. PranaX's differentiation is less about the pitch and more about the plumbing: exclusive IP from a top cancer center, an FDA-registered cGMP facility, and a CEO who has built exosome manufacturing at industrial scale.
Its closest competition includes other exosome and regenerative-biologics firms - the legacy of Codiak BioSciences, plus companies like Direct Biologics, Kimera Labs, and Exopharm - and, more broadly, conventional stem cell therapies and the wellness supplement aisle. PranaX's bet is that owning the supply chain and the patents is the durable advantage.
The business model is a hybrid of B2C and B2B2C: physician-directed supplement sales and paid exosome banking today, with a clinical therapeutics pipeline as the longer game. Aging, notably, is the one market every human eventually enters.
Dr. Steven J. Greco founds PranaX Corporation to commercialize exosome-based regenerative products.
PranaX secures an exclusive exosome technology license from MD Anderson and appoints Phillip Maderia as Chief Executive Officer, effective March 12, 2025.
The exosome technology licensed to PranaX is published in the peer-reviewed journal Nature Communications.
Company closes an oversubscribed $17 million Series A to expand R&D, infrastructure, partnerships, and product commercialization.